 | • レポートコード：D005-00121 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、良性前立腺肥大治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。良性前立腺肥大治療の種類別市場規模（アルファブロッカー、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、用途別市場規模（単独薬物療、併用薬物療）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Abbott Laboratories、Pfizer、Boehringer Ingelheim Pharma GmbH and Co. KG、Allergan plc、Merck and Co.、Astellas Pharma、Teva Pharmaceutical Industries Limited、GlaxoSmithKline plc、Eli Lilly and Company、Sanofi ・地域別グローバル市場分析 2015年-2020年 ・良性前立腺肥大治療の北米市場（アメリカ、カナダ、メキシコ） ・良性前立腺肥大治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・良性前立腺肥大治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・良性前立腺肥大治療の南米市場（ブラジル、アルゼンチン） ・良性前立腺肥大治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アルファブロッカー、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他 ・用途別分析：単独薬物療、併用薬物療 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Benign Prostatic Hyperplasia Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.3% in the forecast period of 2020 to 2025 and will expected to reach USD 7532.5 million by 2025, from USD 6626.4 million in 2019.
The Benign Prostatic Hyperplasia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Benign Prostatic Hyperplasia Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Benign Prostatic Hyperplasia Therapeutics market has been segmented into:
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
By Application, Benign Prostatic Hyperplasia Therapeutics has been segmented into:
Mono Drug Therapy
Combination Drug Therapy
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Benign Prostatic Hyperplasia Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Benign Prostatic Hyperplasia Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Benign Prostatic Hyperplasia Therapeutics market.
The report offers in-depth assessment of the growth and other aspects of the Benign Prostatic Hyperplasia Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Benign Prostatic Hyperplasia Therapeutics Market Share Analysis
Benign Prostatic Hyperplasia Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Benign Prostatic Hyperplasia Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Benign Prostatic Hyperplasia Therapeutics sales, revenue and market share for each player covered in this report.
The major players covered in Benign Prostatic Hyperplasia Therapeutics are:
Abbott Laboratories
Pfizer
Boehringer Ingelheim Pharma GmbH and Co. KG
Allergan plc
Merck and Co.
Astellas Pharma
Teva Pharmaceutical Industries Limited
GlaxoSmithKline plc
Eli Lilly and Company
Sanofi
Table of Contents
1 Benign Prostatic Hyperplasia Therapeutics Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Therapeutics
1.2 Classification of Benign Prostatic Hyperplasia Therapeutics by Type
1.2.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type in 2019
1.2.3 Alpha Blocker
1.2.4 5-Alpha Reductase Inhibitor
1.2.5 Phosphodiesterase-5 Inhibitor
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Therapeutics Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Mono Drug Therapy
1.3.3 Combination Drug Therapy
1.4 Global Benign Prostatic Hyperplasia Therapeutics Market by Regions
1.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Benign Prostatic Hyperplasia Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Benign Prostatic Hyperplasia Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Abbott Laboratories SWOT Analysis
2.1.4 Abbott Laboratories Product and Services
2.1.5 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pfizer SWOT Analysis
2.2.4 Pfizer Product and Services
2.2.5 Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Boehringer Ingelheim Pharma GmbH and Co. KG
2.3.1 Boehringer Ingelheim Pharma GmbH and Co. KG Details
2.3.2 Boehringer Ingelheim Pharma GmbH and Co. KG Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Boehringer Ingelheim Pharma GmbH and Co. KG SWOT Analysis
2.3.4 Boehringer Ingelheim Pharma GmbH and Co. KG Product and Services
2.3.5 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Allergan plc
2.4.1 Allergan plc Details
2.4.2 Allergan plc Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Allergan plc SWOT Analysis
2.4.4 Allergan plc Product and Services
2.4.5 Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Merck and Co.
2.5.1 Merck and Co. Details
2.5.2 Merck and Co. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Merck and Co. SWOT Analysis
2.5.4 Merck and Co. Product and Services
2.5.5 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Astellas Pharma
2.6.1 Astellas Pharma Details
2.6.2 Astellas Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Astellas Pharma SWOT Analysis
2.6.4 Astellas Pharma Product and Services
2.6.5 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Teva Pharmaceutical Industries Limited
2.7.1 Teva Pharmaceutical Industries Limited Details
2.7.2 Teva Pharmaceutical Industries Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Teva Pharmaceutical Industries Limited SWOT Analysis
2.7.4 Teva Pharmaceutical Industries Limited Product and Services
2.7.5 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 GlaxoSmithKline plc
2.8.1 GlaxoSmithKline plc Details
2.8.2 GlaxoSmithKline plc Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 GlaxoSmithKline plc SWOT Analysis
2.8.4 GlaxoSmithKline plc Product and Services
2.8.5 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Eli Lilly and Company
2.9.1 Eli Lilly and Company Details
2.9.2 Eli Lilly and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Eli Lilly and Company SWOT Analysis
2.9.4 Eli Lilly and Company Product and Services
2.9.5 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Sanofi
2.10.1 Sanofi Details
2.10.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Sanofi SWOT Analysis
2.10.4 Sanofi Product and Services
2.10.5 Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Benign Prostatic Hyperplasia Therapeutics Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Regions
4.2 North America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
5.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
5.2 USA Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
6.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
7.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
7.2 China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries
8.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Benign Prostatic Hyperplasia Therapeutics by Countries
9.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type (2019-2024)
10.3 Alpha Blocker Revenue Growth Rate (2015-2025)
10.4 5-Alpha Reductase Inhibitor Revenue Growth Rate (2015-2025)
10.5 Phosphodiesterase-5 Inhibitor Revenue Growth Rate (2015-2025)
10.6 Others Revenue Growth Rate (2015-2025)
11 Global Benign Prostatic Hyperplasia Therapeutics Market Segment by Application
11.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application (2019-2024)
11.3 Mono Drug Therapy Revenue Growth (2015-2020)
11.4 Combination Drug Therapy Revenue Growth (2015-2020)
12 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast (2021-2025)
12.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast (2021-2025)
12.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Benign Prostatic Hyperplasia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Abbott Laboratories Corporate Information, Location and Competitors
Table 6. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Major Business
Table 7. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. Abbott Laboratories SWOT Analysis
Table 9. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 10. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Pfizer Corporate Information, Location and Competitors
Table 12. Pfizer Benign Prostatic Hyperplasia Therapeutics Major Business
Table 13. Pfizer Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Pfizer SWOT Analysis
Table 15. Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 16. Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Boehringer Ingelheim Pharma GmbH and Co. KG Corporate Information, Location and Competitors
Table 18. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Major Business
Table 19. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Boehringer Ingelheim Pharma GmbH and Co. KG SWOT Analysis
Table 21. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 22. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Allergan plc Corporate Information, Location and Competitors
Table 24. Allergan plc Benign Prostatic Hyperplasia Therapeutics Major Business
Table 25. Allergan plc Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Allergan plc SWOT Analysis
Table 27. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 28. Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Merck and Co. Corporate Information, Location and Competitors
Table 30. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Major Business
Table 31. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Merck and Co. SWOT Analysis
Table 33. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 34. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Astellas Pharma Corporate Information, Location and Competitors
Table 36. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Major Business
Table 37. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Astellas Pharma SWOT Analysis
Table 39. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 40. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Teva Pharmaceutical Industries Limited Corporate Information, Location and Competitors
Table 42. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Major Business
Table 43. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Teva Pharmaceutical Industries Limited SWOT Analysis
Table 45. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 46. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. GlaxoSmithKline plc Corporate Information, Location and Competitors
Table 48. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Major Business
Table 49. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. GlaxoSmithKline plc SWOT Analysis
Table 51. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 52. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Eli Lilly and Company Corporate Information, Location and Competitors
Table 54. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Major Business
Table 55. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. Eli Lilly and Company SWOT Analysis
Table 57. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 58. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Sanofi Corporate Information, Location and Competitors
Table 60. Sanofi Benign Prostatic Hyperplasia Therapeutics Major Business
Table 61. Sanofi Benign Prostatic Hyperplasia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 62. Sanofi SWOT Analysis
Table 63. Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 64. Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 66. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players (2015-2020)
Table 67. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Regions (2015-2020)
Table 69. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
Table 70. North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Table 71. Europe Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Countries (2015-2020)
Table 74. South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Table 77. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 78. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type (2015-2020)
Table 79. Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Type (2021-2025)
Table 80. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2015-2020)
Table 81. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application (2015-2020)
Table 82. Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Application (2021-2025)
Table 83. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Benign Prostatic Hyperplasia Therapeutics Picture
Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type in 2019
Figure 3. Alpha Blocker Picture
Figure 4. 5-Alpha Reductase Inhibitor Picture
Figure 5. Phosphodiesterase-5 Inhibitor Picture
Figure 6. Others Picture
Figure 7. Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application in 2019
Figure 8. Mono Drug Therapy Picture
Figure 9. Combination Drug Therapy Picture
Figure 10. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Benign Prostatic Hyperplasia Therapeutics Revenue Market Share in 2019
Figure 19. Global Top 10 Players Benign Prostatic Hyperplasia Therapeutics Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 23. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Regions in 2018
Figure 24. North America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Europe Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. South America Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 30. North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2019
Figure 31. USA Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2019
Figure 36. Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. UK Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2019
Figure 43. China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2019
Figure 50. Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type (2015-2020)
Figure 59. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type in 2019
Figure 60. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Type (2021-2025)
Figure 61. Global Alpha Blocker Revenue Growth Rate (2015-2020)
Figure 62. Global 5-Alpha Reductase Inhibitor Revenue Growth Rate (2015-2020)
Figure 63. Global Phosphodiesterase-5 Inhibitor Revenue Growth Rate (2015-2020)
Figure 64. Global Others Revenue Growth Rate (2015-2020)
Figure 65. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application (2015-2020)
Figure 66. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application in 2019
Figure 67. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Application (2021-2025)
Figure 68. Global Mono Drug Therapy Revenue Growth Rate (2015-2020)
Figure 69. Global Combination Drug Therapy Revenue Growth Rate (2015-2020)
Figure 70. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
胃食道逆流症（GERD）治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Gastroesophageal Reflux Disease (GERD) Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.6% in the forecast period of 2020 to 2025 and will expected to reach USD 4989.6 million by 2025, from USD 4870.2 milli…- ヒストンデアセチラーゼ（HDAC）阻害剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Histone Deacetylase (HDAC) Inhibitor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Histone …
- 免疫チェックポイント阻害剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Immune Check Point Inhibitor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Immune Check Poi…
- 脳卒中診断＆治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Stroke Diagnostics and Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.6% in the forecast period of 2020 to 2025 and will expected to reach USD 27550 million by 2025, from USD 23000 million in 2019. The St…
- リソソーム蓄積症治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Lysosomal Storage Diseases Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Lysos…